drugset / Trial / NCT00170001

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

NCT00170001

Completed 500 enrolled Mayo Clinic AstraZeneca · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators hypothesize that persons with the particular cluster of symptoms that are due to supraesophageal reflux (SER) will have complete resolution of those symptoms with adequate acid suppression when a PPI is administered for 6 months.

Timeline

Start
2005-04
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 40 mg